title: Dissociation of LPL and LDL: effects of lipoproteins and anti-apoB antibodies.
abstract: We have shown previously that the activity of lipoprotein lipase (LPL), the major enzyme responsible for hydrolysis of triglyceride contained in circulating lipoproteins, is associated with lipoproteins in postheparin plasma. In other studies, microtiter plate assays showed that LPL interaction with low density lipoprotein (LDL) and very low density lipoprotein (VLDL) was decreased by antibodies to apolipoprotein (apo)B. To test whether antibodies to apoB affected LPL-LDL association in solution, two types of assays were performed, gel filtration and coprecipitation. First we showed that LPL activity and immunoreactive mass co-eluted during gel filtration of normal postheparin plasma, approximately with the peak of low density lipoproteins. Then LPL was used for gel filtration studies in the presence and absence of LDL and anti-apoB monoclonal antibodies. LPL association with LDL was diminished by antibodies to the amino-terminal region of apoB; antibodies to the carboxyl-terminal LDL receptor binding region of apoB were less effective. LDL binding to LPL containing heparin-agarose was also disrupted by the amino-terminal antibodies to apoB. To determine the LPL-lipoprotein association in situations in which the distribution of plasma lipoproteins was altered, we studied plasma from two types of subjects with dyslipidemias. The addition of 125I-labeled LPL to type 1 postheparin plasma produced two peaks of radioactivity, one peak eluted in the void volume of the column (with the chylomicrons) and a second peak eluted just prior to the normal elution of low density lipoproteins. In postheparin plasma from an abetalipoproteinemic subject, LPL eluted with HDL. We conclude that LPL associates primarily with apoB-containing lipoproteins. The reason for this appears to be that LPL interacts with the apoB.
authors.affiliation: Department of Medicine, Columbia University College of Physicians & Surgeons, New York, NY, USA.
authors.forename: S Y
authors.initials: SY
authors.lastname: Choi
authors.forename: L
authors.initials: L
authors.lastname: Pang
authors.forename: P A
authors.initials: PA
authors.lastname: Kern
authors.forename: H J
authors.initials: HJ
authors.lastname: Kayden
authors.forename: L K
authors.initials: LK
authors.lastname: Curtiss
authors.forename: T M
authors.initials: TM
authors.lastname: Vanni-Reyes
authors.forename: I J
authors.initials: IJ
authors.lastname: Goldberg
mesh_terms: D000911:Antibodies, Monoclonal; D000925:Anticoagulants / Q000494:pharmacology; D001055:Apolipoproteins B / Q000097:blood / Q000276:immunology*; D016022:Case-Control Studies; D011232:Chemical Precipitation; D002850:Chromatography, Gel; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008071:Lipoprotein Lipase / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood*; D012016:Reference Values
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D001055:Apolipoproteins B; D008077:Lipoproteins, LDL; D006493:Heparin; D008071:Lipoprotein Lipase